Bristol-Myers Squibb Company Ce

Bristol-Myers Squibb Company Ce

CELG-RI - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$326.68M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Bristol-Myers Squibb Company CeBristol-Myers Squibb Company Ce143.97%39%-1.9

Earnings Call Q3 2026

October 29, 2026 - AI Summary

Strong Q3 growth + guidance raised (core financial outlook) - Total revenue: $13.1B (+7% YoY). - Growth portfolio revenue: $7.7B (+12% YoY); company highlighted “double digit growth” across multiple differentiated brands. - Full-year guidance raised based on year-to-date performance and outlook for the remainder of 2026. - Non-GAAP EPS (2026): updated to $6.35–$6.55 (midpoint increase of about +$0.15/share excluding the Q3 acquired-in-process R&D + licensing income). - Legacy portfolio outlook: now expected -3% to -5% (reflects generic/LOE pressure). - Eliquis outlook: reiterated +20% to +25% full-year growth range. - Balance sheet / cash flow: ~$13B in cash equivalents + marketable securities (Sept 30); ~$4.2B operating cash flow in the quarter.
Key business drivers: growth brands broadly performing well (what’s “good”) - Multiple growth engines cited with notable momentum: - Eliquis: $4.7B (+26% YoY) on net price + demand + market share; company flagged Q4 pressure in Europe from upcoming LOE, partially offset by U.S. growth. - Opdivo transition impacts: Opdivo -6% YoY to $2.4B, driven by conversion to Qvantig (U.S. + Europe). - Qvantig: $334M, +28% sequential, annualizing at >$1.3B (strong launch trajectory). - Reblozyl: $750M (+22% YoY). - Breyanzi: $526M (+48% YoY). - Camzyos: $420M (+42% YoY); sequential dip attributed to typical inventory drawdown expected to normalize in Q4. - Sotyktu: +25% YoY growth (immunology). - Cobenfy: $57M (+33% YoY) but management said sequential performance was distorted by inventory destocking, expecting revenue to track prescriptions more closely going forward.
Pipeline momentum: multiple positive registrational readouts + major upcoming catalysts (opportunities) - In the prior ~2 months, management cited positive data/readouts from 4 registrational studies, including: - Symvexis (CELMoD): company said FDA accelerated approval obtained (new CELMoD entry). Management is encouraged by Phase 3 progression-free survival (PFS); data to be presented at ASH in December. - Admilparant (IPF): Phase 3 HARMONi-6 met primary endpoint at 60 mg; favorable safety; company expects Phase 3 progressive pulmonary fibrosis results in Q1 2027. - RAISE 101 (alpha RPT in GEP-NETs): interim readouts show clinically meaningful PFS improvement vs progression after lutetium therapy; FDA engagement for next regulatory steps. - Arlocell (GPRC5D-directed CAR T): positive registrational quintessential results in Sept (post-BCMA quadruple-exposed setting). - Upcoming expected 2026–2027 milestones called out: - Before year-end 2026: Phase 3 data for Milvexian (secondary stroke prevention) and Sotyktu (lupus). - Milvexian: additional data for AFib expected in Q1 2027. - ADEPT program (Alzheimer’s disease psychosis): open-label ADEPT-1/ADEPT-3 data at CTAD next month; randomized trials readouts expected through 2027. - Glauc(at)amide (frontline high-risk LBCL) first registrational data expected in 2027.

Exclusive for Stockcircle Pro members

Sign upSign Up

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$326.68 Million
Enterprise Value$35.56 Billion
Dividend yield3.97%
Earnings per Share$3.46
Beta-0.47
Outstanding Shares2,043,000,000

Return

Return on Equity39.49%ROE
Return on Assets10.41%
Return on Invested Capital14.61%

Valuation & Multiples

P/E Ratio14.03P/E Ratio
PEG-791.98PEG
Price to Sales0.01Price to Sales
Price to Book Ratio0.01Price to Book Ratio
Enterprise Value to Revenue0.71
Enterprise Value to EBIT3.48
Enterprise Value to Net Income3
Total Debt to Enterprise1.26
Debt to Equity1.91Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
October 29, 2026
EPS
$1.06
Est. $1.72
Revenue
$13.07 B
Est. $12.59 B

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.01%▼ 0.01%
Total Invested$19,504▼ 26.39%
Investors Holding7▼ 7.00%

About Bristol-Myers Squibb Company Ce

34,100 employees
CEO: Christopher S. Boerner

Bristol Myers Squibb Company (BMS) operates as a biopharmaceutical enterprise, managing the entire lifecycle of its therapeutic products, from initial discovery and development to manufacturing, marketing, and distribution. Its diverse p...

Bristol-Myers Squibb Company Ce Insider Information FAQ

Stockcircle shows 3 open-market insider sales for Bristol-Myers Squibb Company Ce in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.